• P16 Beyond PFS and OS: Recovering Pre- and Post-Progression Survival From Survival Curves

    Dec 1, 2025, 00:00

  • HPR34 Barriers and Policy Solutions in Off-Patent Drug Repurposing: A Full-Life-Cycle Perspective

    Dec 1, 2025, 00:00

  • HTA78 Comparative Analysis of Reimbursement Landscapes: Advantages and Challenges of Bispecifics vs. CAR-T Therapies

    Dec 1, 2025, 00:00

  • EE711 The Impact of Adherence on the Value Assessment of Cardiovascular Interventions: A Systematic Literature Review of Economic Evaluations

    Dec 1, 2025, 00:00

  • EE548 Incorporating Environmental Impact Into Health Economic Evaluations: A Review of Methodological Approaches and Practical Applications

    Dec 1, 2025, 00:00

  • RWD68 Economic and Clinical Burden of MACE-Related Rehospitalizations in Patients With Obesity: A Real-World Study Based on Italian Healthcare Data

    Dec 1, 2025, 00:00

  • HTA201 Influence of NICE Real-World Evidence Framework on HTA Submissions: Sensitivity Analyses in Real-World External Control Arm Studies

    Dec 1, 2025, 00:00

  • HTA33 Analysis of the Implementation of Additive PICOs in a European Joint Health Technology Assessment Implications of EUHTA for Pharma: A Qualitative Exploration

    Dec 1, 2025, 00:00

  • EE405 Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel

    Dec 1, 2025, 00:00

  • EE576 Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment

    Dec 1, 2025, 00:00

  • EE139 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • CO85 Effectiveness of Inclisiran and Evolocumab in LDL-C Goal Attainment: A Hybrid Decision Tree-Markov Model Analysis

    Dec 1, 2025, 00:00

  • EE394 Economic Evaluations of Medication Safety Interventions in Primary Care: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • PT13 Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era

    Dec 1, 2025, 00:00

  • PCR79 Evaluating GenAI vs. Human Screenshot Review Outputs in eCOA Localization: Does AI Hold the Key to Improved Feedback?

    Dec 1, 2025, 00:00

  • HTA345 Uncertainty About How to Translate JCA Into National HTA Submissions (EU-4 and Poland): A Systematic Comparison From an Industry Perspective

    Dec 1, 2025, 00:00

  • EE713 The Impact of Delaying Access to Innovative Therapies in Emerging Markets for Chronic Lymphocytic Leukemia: A Modeling Study

    Dec 1, 2025, 00:00

  • EE226 Cost-Effectiveness and Impact of Nirmatrelvir/Ritonavir in Reducing Hospitalizations Among Elderly COVID-19 Patients in Sweden

    Dec 1, 2025, 00:00

  • Table of Contents

    Dec 1, 2025, 00:00

  • HTA96 Cost-Effectiveness Assessment of Orphan Drugs in Fran Key Insights from CEESP Reviews (2021-2024)

    Dec 1, 2025, 00:00

  • RWD181 The Use of Oligometastatic Disease in Routine Radiology Practi A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • HPR13 Acceptance of Clinical Studies Conducted in Nonus Settings by the FDA Based on the Analysis of Selected Novel Drug Approvals

    Dec 1, 2025, 00:00

  • MSR209 Understanding Drivers on Healthcare Resource Utilization Costs Among People Living With Obesity in UK Clinical Practice

    Dec 1, 2025, 00:00

  • MSR1 A Comparison of Methods for Missing Covariates in a Meta-Regression Using Data From a Systematic Review on Oral Epithelial Dysplasia

    Dec 1, 2025, 00:00

  • EPH90 Estimation of HER2-Negative Metastatic Breast Cancer Population Eligible for Innovative Treatments in France

    Dec 1, 2025, 00:00

  • EE589 Modeling the Healthcare Burden of Oral Corticosteroid Use in Mexico

    Dec 1, 2025, 00:00

  • EE669 Spillover Effect in Health Utility Values: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR263 Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • HSD124 Variations in Screening and Medication Takeup Rates for Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EE40 Adherence to Guidelines for the Treatment of Diabetes With Modern Antidiabetic Drugs in the Czech Republic: Clinical and Economic Impacts

    Dec 1, 2025, 00:00

  • HTA302 Statistical Analysis of Health Technology Assessment Outcomes in Oncology: An Analysis of Key Clinical Value Drivers in Germany and France

    Dec 1, 2025, 00:00

  • HPR88 External Reference Pricing (ERP) Availability vs. Reimbursement Timelines in Poland and Other European Countries: The Analysis of EURIPID Database

    Dec 1, 2025, 00:00

  • CO139 Impact of Pharmacist-Led Interventions on Health-Related Quality of Life in Diabetic Patients: Assessment Using EQ-5D Domains and Visual Analog Scale

    Dec 1, 2025, 00:00

  • RWD32 Characterizing Comorbidities and Co-Occurring Conditions in Adults with Generalized Anxiety Disorder in the United States

    Dec 1, 2025, 00:00

  • EE600 Optimizing Colorectal Cancer Screening in the Czech Republic: Cost-Effectiveness of Lowering the Starting Age to 45 and Introducing an Upper Limit

    Dec 1, 2025, 00:00

  • EPH82 Epidemiology of Diabetes Mellitus in Pregnancy in Hungary: Trends and Future Projections

    Dec 1, 2025, 00:00

  • EPH117 Group A Streptococcal Infections—Diagnostic Approaches and Antibiotics Prescriptions in Children and Adolescents in Germany: A Nationwide Representative Claims Data Analysis

    Dec 1, 2025, 00:00

  • MSR190 Structured Expert Elicitation for Survival Outcomes: Insights From NICE Technical Support Document 26

    Dec 1, 2025, 00:00

  • EE121 Cardiovascular Disease Risk-Reducing Strategies in Qatari Diabetes Patients: A Cost-Effectiveness Study

    Dec 1, 2025, 00:00

  • EE574 Measures for Integrating Carbon Footprints Into Economic Evaluations: A Targeted Review of Environmental and Economic Metrics

    Dec 1, 2025, 00:00

  • PCR194 Protocol for a Health Preference Study on Digital Health Interventions: Integrating DCE and BWS to Capture Subject, Interaction, System, and Societal Value

    Dec 1, 2025, 00:00

  • EE684 Technical Validation of Health Economic Models: Is There a Gold Standard? Assessment and Refinement of Current Checklist Tools

    Dec 1, 2025, 00:00

  • HPR60 Diverging Impacts of Evergreening and Biosimilars on Trastuzumab Utilization and Costs in South Korea: Implications for Sustainable Access and Market Competition

    Dec 1, 2025, 00:00

  • MT9 Clinical Outcomes of Early Diagnosis of Infections of Sterile Body Fluids: A Living Systematic Review and Meta Analysis

    Dec 1, 2025, 00:00

  • EE266 Cost-Effectiveness of Perioperative Pembrolizumab for Early Stage Non-Small Cell Lung Cancer (NSCLC) in Greece

    Dec 1, 2025, 00:00

  • HSD14 Biologic Treatment Patterns and Phenotyping in Severe Uncontrolled Asthma: A Multinational Study

    Dec 1, 2025, 00:00

  • EE349 Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China

    Dec 1, 2025, 00:00

  • EPH216 Social Inequality in the Uptake of Varicella Vaccination: A Danish Nationwide Observational Study

    Dec 1, 2025, 00:00

  • CO190 Prognostic Accuracy and Clinical Effectiveness of 68Ga-PSMA-11 PET/CT (ILLUCIX®) Imaging Followed by 177-Lu-PSMA-617 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • RWD59 Development and Evaluation of a Proactive Monitoring Model for Adverse Drug Events in Patients With Pulmonary Arterial Hypertension Based on the Delphi and Real-World Data

    Dec 1, 2025, 00:00

  • EE176 Cost Of Adverse Events Associates With the Management of Invasive Mold Disease With Isavuconazole Compared With Voriconazole in Spain

    Dec 1, 2025, 00:00

  • PCR190 Predicting Self-Efficacy in Managing Type 2 Diabetes: Results From a Low-Income, Less Educated Community of Quetta City, Pakistan

    Dec 1, 2025, 00:00

  • EPH260 Trends in Epidemiology and Mortality of Patients With Bladder Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2025, 00:00

  • MSR176 Q-Squared as a Mapping Model Performance Metric in Gastrointestinal Disease

    Dec 1, 2025, 00:00

  • EE67 Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection

    Dec 1, 2025, 00:00

  • PCR81 Evaluating Patient Preferences for Clinical Trial Endpoints in Early Stage Cancer: A Discrete Choice Experiment in Canada

    Dec 1, 2025, 00:00

  • HTA142 Evolving JCA Perspectives From EU Stakeholders and the Impact on Manufacturers

    Dec 1, 2025, 00:00

  • EPH233 The Epidemiology Burden and Management of Chronic Hand Eczema in Adolescents: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EPH81 Epidemiology of Breast Cancer in France

    Dec 1, 2025, 00:00

  • EE638 Real-World Healthcare Resource Utilization in Individuals With Phenylketonuria: A Retrospective Observational Study in the United States

    Dec 1, 2025, 00:00

  • EPH93 Evaluating the Potential Health and Economic Impact of V116 vs. PCV20 on Invasive Pneumococcal Disease Among Adults in the United Kingdom

    Dec 1, 2025, 00:00

  • HPR84 Evolving Trends in US Healthcare Policy: Perspectives From US Formulary Decision Makers

    Dec 1, 2025, 00:00

  • EE8 A Cost per Responder Analysis of Lipid-Lowering Therapies in Patients With Established Atherosclerotic Cardiovascular Disease in Italy

    Dec 1, 2025, 00:00

  • EE368 Economic Burden Utilities and Cost-Effectiveness of the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EPH83 Epidemiology of Wilson's Disease in Europe: A Literature Review

    Dec 1, 2025, 00:00

  • CO184 Predictors of Postoperative Complications Following Cytoreductive Surgery With HIPEC: A Real-World Analysis of 493 Patients in Québec

    Dec 1, 2025, 00:00

  • HPR95 Financial Impact of EU MDR Complian A Cost-Mapping Assessment for Manufacturers

    Dec 1, 2025, 00:00

  • MSR51 Can an Ensemble Machine-Learning Approach Outperform Traditional Models While Enhancing Accuracy, Fairness, and Interpretability in Clinical Risk Prediction?

    Dec 1, 2025, 00:00

  • HTA29 AI in Evidence Synthesis: Have We Reached the Promised Land or Are We Still Wandering the Desert?

    Dec 1, 2025, 00:00

  • EE4 A Budget Impact Model of Switching From Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring for Individuals With Type 2 Diabetes Mellitus Receiving Basal Insulin in Italy

    Dec 1, 2025, 00:00

  • RWD161 Real-World Insights Into Prostate Cancer Management Using Electronic Health Record-Derived Data From the UK

    Dec 1, 2025, 00:00

  • HSD10 Assessing the Quality and Determinants of Referrals From General Practitioners (Primary Care Physicians for Adults) to Specialist Physicians in the Cyprus Healthcare System

    Dec 1, 2025, 00:00

  • RWD86 From Clinic to Cohort: The VOICE Vitiligo Registry and Bioresource as a Blueprint for High-Fidelity Specialist Registries

    Dec 1, 2025, 00:00

  • EE362 Economic Burden of Pneumococcal Disease—Impact of Age and Underlying Medical Conditions

    Dec 1, 2025, 00:00

  • MSR220 What About a Latent Cure Model? Assessing Cure Models’ Performance in Pediatric Acute Lymphoblastic Leukemia Treated With Tisagenlecleucel

    Dec 1, 2025, 00:00

  • RWD25 Best Practices Framework for Real-World Data (RWD) in Regulatory Submissions

    Dec 1, 2025, 00:00

  • EPH205 Real-World Treatment Patterns of Trofinetide in Rett Syndrome: Analysis of Medical Pharmacy-Linked Claims Database in the United States

    Dec 1, 2025, 00:00

  • EE707 The Economic Value of Self-Administered Subcutaneous Immunoglobulin G (SCIg) in Canada: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR215 The Value of Medical Spending in China, 1991-2019

    Dec 1, 2025, 00:00

  • HTA336 The Value Flower in Bloom: Emerging Recognition of Uncaptured Benefits in NICE HTA Decisions

    Dec 1, 2025, 00:00

  • RWD185 Trends and Disparities in Prostate Cancer Incidence Prevalence and Survival: A SEER Analysis 2000-2022

    Dec 1, 2025, 00:00

  • RWD99 Identification of Real-World Data to Study HAE Unmet Need: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA114 Diverging Health Technology Assessment Outcomes Between SMC and HAS: A Focus on the Role of Indirect Treatment Comparisons

    Dec 1, 2025, 00:00

  • RWD29 Characteristics of Real-World Data Landscape in Italy: A Scoping Review

    Dec 1, 2025, 00:00

  • MSR95 Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

    Dec 1, 2025, 00:00

  • HTA315 The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)

    Dec 1, 2025, 00:00

  • RWD186 Trends of Prescriptions for Medical Technologies Not Covered by the Colombian Health Benefits Package Between 2020 and 2024: A Descriptive Study

    Dec 1, 2025, 00:00

  • EPH60 Development of a Markov Model-Based Visualization Tool of Regional HPV Vaccination Coverage Rates Over Time in Austria: Combining Data From Pharmaceutical Industry and Healthcare Data Including National Vaccination Registry

    Dec 1, 2025, 00:00

  • EE106 Budget Impact of Implementing a Case-Finding Program in UK Patients at High Risk for COPD to Explore Cost Savings Due to Earlier Diagnosis

    Dec 1, 2025, 00:00

  • HTA43 Artificial Intelligence-Based Population, Intervention, Comparator, and Outcome (PICO) Prediction for European Union (EU) Joint Clinical Assessment (JCA)

    Dec 1, 2025, 00:00

  • EPH237 The Health Impact of Pembrolizumab for the First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC) That Expresses High Levels of PD-L1 in Türkiye

    Dec 1, 2025, 00:00

  • HTA207 Integrating Patient Perspectives Into Drug Reimbursement Decisions: Insights From Taiwan’s Deliberative HTA Process

    Dec 1, 2025, 00:00

  • EPH99 Examining Knowledge Regarding Needlestick Injuries Among Students in Higher Healthcare Education

    Dec 1, 2025, 00:00

  • HTA309 Systematic Review of Value Assessment Frameworks for Digital Health Interventions: Toward a Multidimensional Evaluation Approach

    Dec 1, 2025, 00:00

  • HSD11 Assessing the Quality of Hemophilia Care: How Suitable Are Patient-Centered Outcomes to Compare Hospital Performance?

    Dec 1, 2025, 00:00

  • EE730 Thecosystem: A Systemwide Health and Social Care Decision Analytical Model to Assess Population-Based Interventions for Older People’s Care in the UK

    Dec 1, 2025, 00:00

  • MT47 Variation in Revisions and Complications After Proximal Femoral Fracture Fixation—Association With Provider Characteristics

    Dec 1, 2025, 00:00

  • SA103 What Makes a Medicine Innovative? A Literature Review of Evaluation Frameworks

    Dec 1, 2025, 00:00

  • SA72 Network Meta-Analysis of Survival Outcomes in the First-Line Treatment of Unresectable or Metastatic Melanoma: Scoping Review of Methodology

    Dec 1, 2025, 00:00

  • EE147 Complement C5 Inhibitor (Anti-C5) and Neonatal Fc Receptor Antagonist Anti-FcRn in Myasthenia Gravis at University Public Hospitals of Paris, France (AP-HP): What Is the Market Share of These New Treatments?

    Dec 1, 2025, 00:00

  • EE205 Cost-Effectiveness Analysis of Inhaled Levodopa for Managing OFF Episodes in Patients With Parkinson’s Disease

    Dec 1, 2025, 00:00

  • EE200 Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective

    Dec 1, 2025, 00:00

  • Patient-Reported Outcomes Now and Into the Future: Multistakeholder Perspectives on Optimizing the Use of Patient-Reported Outcome Evidence in Decision Making Across the US Healthcare Continuum

    Dec 1, 2025, 00:00

  • MT38 Standardizing Healthtech Evidence to Meet NICE Expectations

    Dec 1, 2025, 00:00

  • EPH279 Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Ukraine and in Kiev City, Lviv, and Cherkasy Regions

    Dec 1, 2025, 00:00

  • PCR153 Meaningful Within-Patient Change of the IWQOL-Lite-CT Physical Function Composite in Adults With Obesity

    Dec 1, 2025, 00:00

  • EE614 Preventing Stunting Through Early Nutritional Intervention: Effectiveness and Economic Evaluation in Children With Weight Faltering

    Dec 1, 2025, 00:00

  • EE351 Economic and Social Burden of Pulmonary Hypertension in Italy

    Dec 1, 2025, 00:00

  • HTA166 Guidance for Real-World Evidence Generation for the Joint Clinical Assessment Process and Its Implications for Country-Specific HTA Body Acceptability

    Dec 1, 2025, 00:00

  • SA34 Direct Healthcare Costs (HCCs) Inequalities Associated With Myasthenia Gravis (MG) in Hungary: Claims Database Analysis

    Dec 1, 2025, 00:00

  • EE712 The Impact of Burosumab on the Clinical and Economic Burden of X-Linked Hypophosphatemia in Adult Patients in France

    Dec 1, 2025, 00:00

  • RWD146 Real-World Adherence to Nonhormonal Therapies for Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE167 Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model

    Dec 1, 2025, 00:00

  • The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs

    Dec 1, 2025, 00:00

  • EE305 Cost-Utility Analysis of Multiplex Cell Culture Technology for Predicting Carboplatin Plus Paclitaxel-Induced Side Effects in Cancer Care

    Dec 1, 2025, 00:00

  • SA69 Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review

    Dec 1, 2025, 00:00

  • HTA39 Are We SEEing It Yet? The Use of Structured Expert Elicitation Protocols for Decision Making

    Dec 1, 2025, 00:00

  • EPH59 Development and Validation of a Case Identification Algorithm for Hand Trauma Patients Using Health Administrative Data and the Epidemiology of Hand Trauma in a Universal Healthcare System

    Dec 1, 2025, 00:00

  • PCR207 Real-World Socioeconomic Burden and Health-Related Quality of Life (HRQoL) for Patients Living with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the UK: Results From an Online Patient Survey

    Dec 1, 2025, 00:00

  • CO68 Data Visualization of Treatment Patterns in Adults With BRAFV600E Mutant mNSCLC in Real-World Settings

    Dec 1, 2025, 00:00

  • EPH32 Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • EE421 Estimating Life-Years and QALYs Gained From Tumor Treating Fields in Newly Diagnosed Glioblastoma: A US-Based Real-World Survival-Based Model

    Dec 1, 2025, 00:00

  • PT33 Trends in Reimbursement Agreements for Innovative Orphan and Oncological Medicines in Spain 2020-2025

    Dec 1, 2025, 00:00

  • PCR113 Health-Related Quality of Life Among People With Arthritis in Ireland

    Dec 1, 2025, 00:00

  • EPH62 Diabetes Trends in France (2021-2023): A Descriptive Study Based on the THIN Database

    Dec 1, 2025, 00:00

  • HTA271 Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis

    Dec 1, 2025, 00:00

  • PCR174 Patient Perspectives on Mild-Moderate Infection Burden in Multiple Myeloma and Chronic Lymphocytic/Small Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PCR34 Burden of Transfusion in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Results From a Real-World Study in European Countries

    Dec 1, 2025, 00:00

  • HTA280 Reassessment of Orphan Drugs in Germany After Exceeding the Annual Sales Limit of €30 Million: Impact on the Reimbursement Price and Key Influencing Factors

    Dec 1, 2025, 00:00

  • SA37 Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review

    Dec 1, 2025, 00:00

  • RWD57 Design Operating Characteristics in a Noninterventional Study Framework

    Dec 1, 2025, 00:00

  • HTA67 CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?

    Dec 1, 2025, 00:00

  • EE310 Cost-Utility Analysis of the BCIS Conveyance Algorithm for Out-of-Hospital Cardiac Arrest Patients

    Dec 1, 2025, 00:00

  • CO80 Early Life Hypoglycemia and Neurological Sequalae in Children With Congenital Hyperinsulinism

    Dec 1, 2025, 00:00

  • HTA287 Reimbursement Trends for GLP-1s and Emerging Antiobesity Drugs Across Seven Global Markets

    Dec 1, 2025, 00:00

  • EE426 Estimating the Economic Burden of DLBCL: Developing and Testing a Cost of Disease Model

    Dec 1, 2025, 00:00

  • HTA321 The Interim Acceptance and Ultraorphan Pathways in Scotland: An Update

    Dec 1, 2025, 00:00

  • EE56 Assessing Productivity in Health Technology Assessment: A Comparative Review of Human Capital and Friction Cost Approaches in Europe

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • PCR127 Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Myelodysplastic Syndromes (MDS)

    Dec 1, 2025, 00:00

  • MSR37 Artificial Intelligence-Powered Literature Reviews (AILRs): Streamlining Joint Clinical Assessment (JCA) Dossier Preparation for the Next Generation of Pharmaceutical Submissions

    Dec 1, 2025, 00:00

  • HTA351 Use of the ESMO-Magnitude of Clinical Benefit Scale to Guide HTA Recommendations on Coverage and Reimbursement for Cancer Medicines in Ireland: A Retrospective Analysis

    Dec 1, 2025, 00:00

  • HPR17 Advancing INN-Based Prescribing in Saudi Arabia’s Private Sector: Implications for Biologics and Biosimilars Utilization Under CHI Oversight

    Dec 1, 2025, 00:00

  • EE437 Evaluating the Cost-Effectiveness of High-Dose Influenza Vaccination for Adults Aged 60 Years and Older in Austria

    Dec 1, 2025, 00:00

  • EE431 Evaluating Cost-Consequences and Digital Transformation Through Concentric Consent: An Impact Assessment at Oxford University Hospitals NHS Foundation Trust

    Dec 1, 2025, 00:00

  • RWD61 Development and Implementation of a Health and Well-being Index to Inform Risk Management and Patient Engagement in a Colombian Health Insurance Plan

    Dec 1, 2025, 00:00

  • EE720 The Public Health and Economic Effects of Various RSV Vaccination Strategies With RSVpreF Among Adults in France

    Dec 1, 2025, 00:00

  • HTA199 Increased Trends of Self-Optimized Submissions to NICE

    Dec 1, 2025, 00:00

  • EE637 Real-World Healthcare Resource Utilization and Costs by Glycemic Control in People With Type 2 Diabetes: An Observational Population-based Register Study in Sweden

    Dec 1, 2025, 00:00

  • EPH275 Urinary Dysfunction Management in Multiple Sclerosis: A Nationwide Real-Life Analysis From the French SNDS Database

    Dec 1, 2025, 00:00

  • HSD103 Standardizing Point-of-Care mRNA-Based Gene Therapy Production in Europe: A Cost and Capacity Analysis of the Nanospresso Platform

    Dec 1, 2025, 00:00

  • EE533 Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Hospitalization Burden in Norway

    Dec 1, 2025, 00:00

  • RWD69 Economic and Clinical Insights Into Oral Nutritional Supplementation in Oncology: A Brazilian Real-World Study

    Dec 1, 2025, 00:00

  • EE758 Work Complexity in Adults With Phenylketonuria in Sweden in 2020

    Dec 1, 2025, 00:00

  • EPH250 The Longevity Conundrum: Population Aging in the UK

    Dec 1, 2025, 00:00

  • RWD34 Clinical Outcomes and Economic Burden of Acute Lower Respiratory Tract Infection-Related Hospitalizations Among Adults in the United States Post COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • HTA74 Clinical and Economic Factors Underlying QALY Weights and Severity Modifiers in NICE Health Technology Evaluations: An Analysis of Recent Appraisals

    Dec 1, 2025, 00:00

  • CO116 Expert Consensus on the Clinical and Economic Value of Advanced Wound-Care Products in Mexico: Results From a Delphi Panel

    Dec 1, 2025, 00:00

  • RWD88 Gender Inequalities in Aortic and Mitral Valve Interventions in Sweden

    Dec 1, 2025, 00:00

  • CO107 Evaluating the Health Impact of Anti-PD-(L)1 Agents for Early Stage Cancer Treatment in the Czech Republic

    Dec 1, 2025, 00:00

  • EPH9 A Systematic Literature Review to Identify Potential Risk Factors and Causative Organisms for Neonatal Sepsis in Indian Neonates

    Dec 1, 2025, 00:00

  • HPR32 Balancing Cost-Effectiveness With Societal Values: A Representative Survey of Norwegian Attitudes Toward Healthcare Resource Allocation

    Dec 1, 2025, 00:00

  • MSR183 ROBERTA on the Job: A Proof-of-Concept Study of a Customized GPT Tool for Risk-of-Bias Assessment of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • OP9 Gatekeepers of Scien Evolving Publishing Policies in the Age of AI

    Dec 1, 2025, 00:00

  • HTA12 A Retrospective Assessment of Drug Eligibility for NICE’s Highly Specialized Technologies Program Using the 2025 Criteria

    Dec 1, 2025, 00:00

  • HSD92 Real-World Analysis of Treatment Patterns and Disease Exacerbations Among Patients Initiating Therapy for Myasthenia Gravis

    Dec 1, 2025, 00:00

  • HPR111 Harmonization of Drug Policy and Regulation Across Europe: A Comparison Between the European Medicines Agency and the European HTA Regulation

    Dec 1, 2025, 00:00

  • RWD36 Clinical Humanistic and Economic Burden Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA295 Routing Decisions and Outcomes of NICE Technology Appraisals Underproportionate Approach to Technology Appraisals

    Dec 1, 2025, 00:00

  • MSR21 AI-Assisted Systematic Literature Screening According to NICE, UK, and CDA (Canada) Position Papers: An HTA Submission Use Case

    Dec 1, 2025, 00:00

  • MSR83 Eliciting Patients' and Clinicians' Preferences on Adjuvant Treatment for HR+/HER2- Early Breast Cancer: Design of a Probabilistic Threshold Technique in Italy

    Dec 1, 2025, 00:00

  • EE402 Economic Model of Alzheimer's Disease That Incorporates the Uncertainty Associated With Measuring Efficacy in Clinical Trials

    Dec 1, 2025, 00:00

  • EPH116 Grounded Theory Study to Assess Barriers and Reasons for Insufficient Compliance With Valproate Risk Minimization Measures: Example of a Qualitative Method Aligned With the Recommendations of the GVP Module XVI, Addendum II

    Dec 1, 2025, 00:00

  • EE604 Organizational Budget Impact Analysis of the Port-Delivery Platform With SUSVIMO in Age-Related Macular Degeneration (AMD) in France

    Dec 1, 2025, 00:00

  • MSR58 Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study

    Dec 1, 2025, 00:00

  • HPR61 Do Health Technology Assessments (HTA) Consider Racial Health Inequalities? A Case Study of NICE HTAs for Chronic Kidney Disease Hypertension and Diabetes

    Dec 1, 2025, 00:00

  • EE690 The Cost of Pressure: Quantifying the Consequences of Clinical Strain in Ophthalmology

    Dec 1, 2025, 00:00

  • EE671 Stakeholder Engagement in the Economic Evaluation of Site-Specific Wastewater-Based Surveillance for Preventing COVID-19 Outbreaks in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • PCR192 Productivity Impacts and the Need for Carer Support in Obstructive HCM: A Patient and Carer Survey

    Dec 1, 2025, 00:00

  • EE252 Cost-Effectiveness of Genetic Testing for Optimizing Warfarin Therapy in Mechanical Heart Valve Patients: Insights From Qatar

    Dec 1, 2025, 00:00

  • RWD155 Real-World Evidence of Atezolizumab in Unresectable Recurrent NSCLC: Insights From Japan's Next-Generation Medical Infrastructure Act

    Dec 1, 2025, 00:00

  • EE453 Expanded Access to Oncology Therapies in Mexico: The Role of Bioequivalent Abiraterone and Axitinib

    Dec 1, 2025, 00:00

  • MSR110 Flexible Parametric Inference for Cause-Specific Hazard-Competing Risk Models Under Interval Censoring

    Dec 1, 2025, 00:00

  • PCR171 Patient Involvement in Health Technology Assessment: A Global Review of Practices, Purposes, and Pathways

    Dec 1, 2025, 00:00

  • CO9 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal-Bolus Insulin

    Dec 1, 2025, 00:00

  • RWD145 Real-World Insights From the LOGEX IMID Observatory: A Multicountry, Multiyear Analysis of Treatment Pathways and Healthcare Resource Utilization in Immune-Mediated Inflammatory Diseases

    Dec 1, 2025, 00:00

  • HSD110 The Role of a Functional Clinical Staff in Guiding High-Cost Drug and Novel Technology Decision Making: Experience From a Latin American Oncology Clinic

    Dec 1, 2025, 00:00

  • HPR50 Comparison of Alignment Between EMA Indications and National Reimbursement Decisions in Italy for Orphan Drugs

    Dec 1, 2025, 00:00

  • EE112 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in France

    Dec 1, 2025, 00:00

  • HPR178 Revisiting the Willingness-to-Pay Threshold in the Czech Republic: Integrating QALY Shortfall to Reflect Disease Severity and Unmet Medical Need

    Dec 1, 2025, 00:00

  • CO2 A Systematic Literature Review and Meta-Analysis Comparing Robotic-Assisted Mitral Valve Repair Using the Da Vinci Surgical System to Open Mitral Valve Repair

    Dec 1, 2025, 00:00

  • EE184 Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom

    Dec 1, 2025, 00:00

  • P22 Validation of Primary Care Resource Use and Costs in OMOP-Mapped vs. Source CPRD Aurum Data

    Dec 1, 2025, 00:00

  • EE556 Inpatient Cost of Managing Adverse Events (AEs) Associated With Immune Checkpoint Inhibitors (ICI) Approved for Advanced or Metastatic Cancers in the UK

    Dec 1, 2025, 00:00

  • HPR209 The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways

    Dec 1, 2025, 00:00

  • RWD179 The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study

    Dec 1, 2025, 00:00

  • MSR87 Estimand Framework in the Setting of Observational Studies: Current Landscape and Future Directions

    Dec 1, 2025, 00:00

  • PT32 Can Adalimumab Serve as Big Mac Index for Pharmaceutical Prices?

    Dec 1, 2025, 00:00

  • PCR229 The Effects of Disease Modifying Anti-Rheumatic Drugs (DMARDs) on Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analyses

    Dec 1, 2025, 00:00

  • HTA303 Structural Uncertainty (SU) in Model-Based Economics Appraisal (MBEA): A Document Review of the French National Authority for Health (HAS)

    Dec 1, 2025, 00:00

  • EE459 Exploring the Healthcare Resource Utilization (HCRU) Associated With Chorea in Patients With Huntington's Disease (HD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EPH91 Evaluate the Statistical Utility After Transformation of a CDISC SDTM Database Into OMOP CDM

    Dec 1, 2025, 00:00

  • EPH85 Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States

    Dec 1, 2025, 00:00

  • EE443 Evaluating the Economic Value of First-Line (1L) Treatment Strategies for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Insights From the Portuguese Healthcare System

    Dec 1, 2025, 00:00

  • EE283 Cost-Minimization Analysis of Aripiprazole 2-Month Ready-to-Use vs. Other Long-Acting Injectable Antipsychotics: Evidence From Ontario

    Dec 1, 2025, 00:00

  • PCR223 Taking an Equity Lens to Patient-Reported Outcomes and Experiences in Wales Using PROGRESS PLUS: A Population-Based Cross-Sectional Study

    Dec 1, 2025, 00:00

  • HPR160 Physicians' and Pharmacists’ Views on Implementing Generic Medicines Standard and Biosimilar Guide

    Dec 1, 2025, 00:00

  • HTA53 Beyond Productivity: How Professional Identity Shapes Generative AI Adoption Among Medical Writing Professionals

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • PCR197 Psychometric Validation of the Mucopolysaccharidosis Health Assessment Questionnaire (MPS-HAQ) for Mucopolysaccharidosis IVA

    Dec 1, 2025, 00:00

  • PCR180 Patient Preferences for Type 2 Diabetes Mellitus (T2DM) Treatment: A Systematic Review of Discrete Choice Experiments Studies

    Dec 1, 2025, 00:00

  • SA30 Designing Digital Healthcare Professional Surveys: A Methodological Overview

    Dec 1, 2025, 00:00

  • MSR180 Reevaluating Cost-Effectiveness: A Holistic Framework for Assessing Disease-Modifying Treatments in Type 1 Diabetes

    Dec 1, 2025, 00:00

  • EE91 Budget Impact Analysis of Noninvasive Tests Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Diagnosis in Japan

    Dec 1, 2025, 00:00

  • EE419 Estimating Health Utility Decrements Associated With Chronic Disease Outcomes Using MEPS

    Dec 1, 2025, 00:00

  • HTA167 Guidelines for Health Technology Assessment Ministry of Health Sultanate of Oman

    Dec 1, 2025, 00:00

  • HPR187 Socioeconomic Disparities in Postpartum Depression Following Abortion Restrictions: A Difference-in-Differences Analysis of Medicaid Data Post-Dobbs

    Dec 1, 2025, 00:00

  • HTA76 Clinical Evidence Quality in Appraisals of Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • EE652 Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025

    Dec 1, 2025, 00:00

  • PT19 Can Estimands Support Aligned Evidence Generation for EU HTA? Reflections on Their Role in Joint Clinical Assessments, PICO Alignment, and Beyond

    Dec 1, 2025, 00:00

  • EE153 Constructing a Dynamic Budget Impact Model: An AI Pretraining Approach for a New Parkinson's Disease Drug

    Dec 1, 2025, 00:00

  • RWD5 A Real-World Survey of Healthcare Resource Utilization Treatment Usage and Unmet Need for Hemophilia Patients in Spain

    Dec 1, 2025, 00:00

  • HPR19 Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis

    Dec 1, 2025, 00:00

  • RWD168 Risk of Abdominal Hernia Repair in Patients With Intestinal Stoma in Italy: A Real-World Analysis

    Dec 1, 2025, 00:00

  • HSD26 Comparing Countries’ Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States

    Dec 1, 2025, 00:00

  • EE75 Bimekizumab’s Synergistic Economic Impact Across Four Indications in France

    Dec 1, 2025, 00:00

  • HTA54 Beyond RCTs: The Role of Patient Perspectives and Nontraditional Evidence in HTA Decisions for Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • HPR23 Analysis of Clinical and Economic Evidence Focused on RWE in Medicare Drug Price Negotiations: Sacubitril/Valsartan, Rivaroxaban, and Apixaban

    Dec 1, 2025, 00:00

  • HPR231 Unmet Need in IgA Nephropathy (IgAN): Disparity Between Clinical Guidelines and Real-World Practice in Ireland

    Dec 1, 2025, 00:00

  • EPH188 Prevalence and Overlap of Overweight/Obesity Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease in England: A Clinical Practice Research Datalink Study

    Dec 1, 2025, 00:00

  • RWD60 Development and Implementation of a Dynamic Framework for Assessment and Improvement of Registries’ Data Quality

    Dec 1, 2025, 00:00

  • EE572 Mapping the Use of Capability Measures ICECAP-A and O in Economic Evaluations

    Dec 1, 2025, 00:00

  • PCR245 To What Endpoint? Exploring Clinical Outcome Assessments of Pain in Phase 2 and 3 Trials and Drug Labels in Women’s Health Conditions

    Dec 1, 2025, 00:00

  • CO193 Psychometric Evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL for Vasomotor Symptoms Caused by Endocrine Therapy: Reliability, Validity, and Differential Item Functioning

    Dec 1, 2025, 00:00

  • HTA219 Level of ICER of Health Economic Assessment in France in 2024

    Dec 1, 2025, 00:00

  • EPH141 Incidence and Treatment of Squamous-Cell Anal Cancer (SCAC) in Germany: A Retrospective Study in German Statutory Health Insurance (SHI) Claims Data

    Dec 1, 2025, 00:00

  • HSD109 The Real-World Impact of Step Therapy and Prior Authorization on Patients, Clinicians, and US Health Plans: Lessons to Be Learned in Europe

    Dec 1, 2025, 00:00

  • CO76 Does the Abortion Pill Harm Women? Serious Adverse Events Following Mifepristone Abortion in US Commercial and Medicaid Populations

    Dec 1, 2025, 00:00

  • MT5 Artificial Intelligence in Health Economics: Opportunities and Challenges for the Future: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE550 Increased Healthcare Resource Utilization Among Uncontrolled vs. Controlled Hypertension Population: Findings From the EnligHTN Study

    Dec 1, 2025, 00:00

  • HPR89 Facilitating Investment in Obesity Care and Prevention: A Societal Cost Benefit Analysis for the Netherlands

    Dec 1, 2025, 00:00

  • CO86 Effectiveness of Pneumococcal Vaccines in Preventing Otitis Media in Children: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EPH92 Evaluating Performance of the Experimental EQ-TIPS (V3) for Assessing Infants and Toddlers With Acute Infections: A Mixed-Methods Approach of Cognitive Debriefing and Psychometric Testing

    Dec 1, 2025, 00:00

  • HTA155 From License to Reimbursement: A Slot-Based ML Framework for Seamless MA to HTA Alignment

    Dec 1, 2025, 00:00

  • MSR71 Development of an A-Powered Command-Line Agent to Support Methodological Guidance Selection in Health Economics Analysis

    Dec 1, 2025, 00:00

  • EPH183 Postherpetic Neuralgia Occurrence and Herpes Zoster Recurrence in Immunocompromised Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study (Clinical Practice Research Datalink 2012-2019)

    Dec 1, 2025, 00:00

  • EPH94 Evaluation of Participation Data in the Context of Cancer Prevention

    Dec 1, 2025, 00:00

  • CO75 Disease Progression Modeling for an Ultra-Rare Disease: Lysosomal Acid Lipase Deficiency (LAL-D)

    Dec 1, 2025, 00:00

  • EE451 Examining the Opportunity Costs Due to Diabetic Macular Edema Taking Into Account Access Barriers Evaluated in the Barometer Program Survey in Colombia

    Dec 1, 2025, 00:00

  • EE567 Live Attenuated Influenza Vaccination (LAIV) for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EE458 Exploring the Economic Burden Associated With Chronic Obstructive Pulmonary Disease (COPD) Due to Alpha1 Antitrypsin Deficiency (AATD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HPR4 A Comparative Analysis of Regulatory Divergence in Expedited Oncology Approvals: Evidence, Pathways, and Timelines Across FDA, EMA, TGA, and PMDA

    Dec 1, 2025, 00:00

  • EE630 Quantifying the Opportunity Costs of Intra-Direct Oral Anticoagulants (DOAC) Switching Pathways Across the National Health Service (NHS) in England: A Structured Framework

    Dec 1, 2025, 00:00

  • EE127 Clinical and Economic Benefits of Extended-Release Metformin In Prediabetes Management

    Dec 1, 2025, 00:00

  • PCR134 Impacts of Patient-Centered Collaboration: Application of a Continuous Engagement Plan Across Multiple Phases of the Insights and Patient Experiences With Cardiovascular Disease (IPEC) Initiative

    Dec 1, 2025, 00:00

  • HPR168 Quo Vadis? The Emerging Role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in an Evolving Regulatory Landscape

    Dec 1, 2025, 00:00

  • PCR220 Spillover Effects on Informal and Family Caregivers' Utility: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HSD76 Modeling the Environmental and Cost Impact of a Novel Detergent in NHS Endoscope Reprocessing Workflows

    Dec 1, 2025, 00:00

  • EE747 Value-Based Assessment of Trifluridine Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

    Dec 1, 2025, 00:00

  • CO236 The Clinical Burden and Complications Associated With Glycogen Storage Disease Type Ia (GSDIa): Results From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR237 Value of the France Early Access Pathways: Highlighting Benefits for Patients and Industry Sponsors of the Novel Therapeutic Fosmanogepix Addressing High Unmet Clinical Needs in Invasive Fungal Infections

    Dec 1, 2025, 00:00

  • MSR139 Long-Term Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST): Investigating a Parametric Survival Model for Extrapolations

    Dec 1, 2025, 00:00

  • CO12 APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes

    Dec 1, 2025, 00:00

  • HPR240 Who Pays the Price? International Impacts of US Drug-Cost Benchmarking

    Dec 1, 2025, 00:00

  • HPR147 Navigating the MFN Pricing Era: Strategic Imperatives for Biopharma

    Dec 1, 2025, 00:00

  • EE332 Direct Economic Impact of Idiopathic Pulmonary Fibrosis on the Brazilian Private Healthcare System: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • HPR14 Access and Evolving Eviden A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements

    Dec 1, 2025, 00:00

  • HTA3 A Comparison of the NICE HST Program With Health Technology Assessments of Ultra-Orphan Drugs From France and Germany

    Dec 1, 2025, 00:00

  • CO120 Extending Survival in Glioblastoma: Real-World Evidence of Post-Progression Benefit From Tumor-Treating Fields Therapy

    Dec 1, 2025, 00:00

  • CO213 Review of Index Line Selection Methods in Hemato-Oncology Externally Controlled Trials: A Secondary Analysis of the Hermans et al Systematic Review

    Dec 1, 2025, 00:00

  • CO102 Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML

    Dec 1, 2025, 00:00

  • HTA185 HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals

    Dec 1, 2025, 00:00

  • MSR142 Machine Learning to Predict Noncompliance and Program Dropout in Patients Treated for Chronic Diseases: Unsupervised and Supervised Analyses From a Large Multinational Drug Access Program Database

    Dec 1, 2025, 00:00

  • PCR225 The Burden of Cognitive Impairment Associated With Schizophrenia (CIAS) on People With Lived Experience (PWLE): A National Canadian Survey

    Dec 1, 2025, 00:00

  • HTA350 Use of Data From Phase 3 RCTs in Earlier Lines of Therapy in Support of Noncomparative Evidence From Pivotal Phase 2 Studies

    Dec 1, 2025, 00:00

  • SA49 Health-Related Quality of Life Impacts of Living With Primary Lateral Sclerosis (PLS): The Development of a Conceptual Model

    Dec 1, 2025, 00:00

  • EPH2 A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population

    Dec 1, 2025, 00:00

  • EE49 An Interactive R-Shiny Application for Budget Impact Modeling of Cell and Gene Therapies With Multiple Innovative Payment Scenarios

    Dec 1, 2025, 00:00

  • EE19 A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire

    Dec 1, 2025, 00:00

  • EE130 Clinical and Economic Impact of Early Treatment in Relapsing Remitting Multiple Sclerosis With High-Efficacy Disease-Modifying Therapy in Mexico

    Dec 1, 2025, 00:00

  • EE304 Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis

    Dec 1, 2025, 00:00

  • HTA97 Cost-Effectiveness Modeling Challenges and Trends in the Neoadjuvant and Perioperative Settings: A Review of NICE Oncology Submissions

    Dec 1, 2025, 00:00

  • EE377 Economic Evaluation of Cefiderocol for the Treatment of Confirmed MBL-Producing Pathogens in Italy

    Dec 1, 2025, 00:00

  • HPR65 Early Access Programs and Pricing and Reimbursement Agreements in Portugal for Orphan Medicines Centrally Approved in the European Union

    Dec 1, 2025, 00:00

  • EE513 Healthcare Resource Utilization and Economic Burden Among Adults With Alopecia Areata in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • PCR208 Registry Participation in Rare Diseases: Insights from Stakeholders and an Adapted Targeted Literature Review (ATLR)

    Dec 1, 2025, 00:00

  • EE79 Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)

    Dec 1, 2025, 00:00

  • SA70 Modeling the Lifetime Effects of Lecanemab in Early Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EE251 Cost-Effectiveness of First-Line Lorlatinib for ALK-Positive Advanced NSCLC in the UK

    Dec 1, 2025, 00:00

  • EE647 Relationship Between Cost-Effectiveness Threshold and Drug Reimbursement in Spain, Italy, and France

    Dec 1, 2025, 00:00

  • MSR11 Accounting for Cure Rates Estimated from Progression-Free Survival (PFS) in Long-Term Overall Survival (OS) Projections: A Case Study from Previously Treated Advanced Cancers

    Dec 1, 2025, 00:00

  • EE172 Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis

    Dec 1, 2025, 00:00

  • EPH257 Transition Across Cognitive States and Death Among Older Adults With Type 2 Diabetes: Determining the Predictors of Cognitive Decline With a Multistate Markov Model

    Dec 1, 2025, 00:00

  • HTA141 Evolving Assumptions on Treatment Durability in Cost-Effectiveness Models of Cell and Gene Therapies: Insights From French HTA Submissions

    Dec 1, 2025, 00:00

  • CO82 Economic and Clinical Impact of Advanced Therapies in Moderate-to-Severe Rheumatoid Arthritis in Spain: CIARA Study

    Dec 1, 2025, 00:00

  • HTA90 Consideration of Off-Label Therapies as Appropriate Comparator Therapy in Early Benefit Assessments in Germany Under the ALBVVG Legislation

    Dec 1, 2025, 00:00

  • HPR121 Incentivizing Access to New Drugs in Psychiatry: Exploration of a Subscription Payment Approach to Overcome Barriers to European Launch

    Dec 1, 2025, 00:00

  • RWD84 Feasibility Assessment of Real-World Data for Trial Emulations: A Methodological Framework

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • PCR31 Bimekizumab Demonstrated Sustained Long-Term Improvements in Health-Related Quality of Life and Work Productivity in Patients With Active Psoriatic Arthritis: 3-Year Results from Two Phase 3 Studies

    Dec 1, 2025, 00:00

  • EE399 Economic Impact of Incorporating a Fecal Bacterial Signature to Optimize FIT-Based Colorectal Cancer Screening in Spain

    Dec 1, 2025, 00:00

  • EPH8 A Retrospective Study of Treatment Use in Metastatic Colorectal Cancer (mCRC) Based on French Hospital Discharge Database

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • MSR134 Interpreting PRO-CTCAE Data: Defining and Answering the Right Questions

    Dec 1, 2025, 00:00

  • EE373 Economic Evaluation of a Standardized Care Pathway for Nontraumatic Acute Abdominal Pain in the Emergency Department

    Dec 1, 2025, 00:00

  • EE661 Societal and Economic Impact of Targeted Therapy for Breast Cancer in Bulgaria

    Dec 1, 2025, 00:00

  • HPR86 Exploring Off-Label Drug Coding Trends in French Hospitals: A Descriptive and Stratified Analysis 2020-2024

    Dec 1, 2025, 00:00

  • RWD152 Real-World Evidence From Community Oncology: Assessing Secular Trends in Ovarian Cancer Diagnoses From 2014 to 2024

    Dec 1, 2025, 00:00

  • EE742 Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Germany: A Return on Investment Analysis Using an Integrated Actuarial-Macroeconomic Model

    Dec 1, 2025, 00:00

  • HPR228 Understanding the Impact of Cost-Effectiveness Evaluations on Drug Pricing in Japan: A Case Study of Oncology Therapies

    Dec 1, 2025, 00:00

  • EE328 Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework

    Dec 1, 2025, 00:00

  • EPH95 Evaluation of Safety Signal Management in Europe: Insights From PRAC Reports (2016-2024)

    Dec 1, 2025, 00:00

  • PCR269 Why Are Patient-Reported Outcome Measure (PROM) Results Missing From Labels of Obesity Management Medications?

    Dec 1, 2025, 00:00

  • P47 Quality of Life and Utility Values Across the Alzheimer’s Disease Spectrum: Results From the What Matters Most Survey

    Dec 1, 2025, 00:00

  • RWD183 Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data

    Dec 1, 2025, 00:00

  • SA101 Using a Large Language Model (LLM) for Data Extraction of Studies: Learnings From a Targeted Literature Review (TLR) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • EE741 Understanding the Impact of the NICE Severity Modifier: A Targeted Review of Oncology Submissions

    Dec 1, 2025, 00:00

  • EE215 Cost-Effectiveness Analysis of Pediatric and Adult Pneumococcal Conjugate Vaccine Strategies in Canada

    Dec 1, 2025, 00:00

  • HPR138 Market Access Challenges for Oncology Combination Therapies in Europe: A Review of Regulatory Approvals HTA Outcomes and Pricing Dynamics

    Dec 1, 2025, 00:00

  • PCR147 Is There a Lack of Dietary Data Collection in Real-World IBD Studies? Literature Review and Future Considerations

    Dec 1, 2025, 00:00

  • CO262 Utility of Minimum Dataset for Generation of Real-World Data in a Context With Evidence Gaps: The Left Ventricular Assist Devices as Destination Therapy

    Dec 1, 2025, 00:00

  • CO191 Prognostic Factor Evaluation for Clinical Outcomes in HER2-Mutant NSCLC

    Dec 1, 2025, 00:00

  • EE131 Clinical and Economic Impact of Hospital-Acquired Infections by Pseudomonas Aeruginosa in a Tertiary Care Teaching Hospital in India

    Dec 1, 2025, 00:00

  • P26 Approximating Competing Risk Events From Published Kaplan-Meier Curves Using Simultaneity-Based Event Assignment Methods

    Dec 1, 2025, 00:00

  • CO89 Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Breast Cancer: A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE42 The Value of Investing in Innovative Medicines: A Scalable Approach to Measure the Lifetime Social Impact

    Dec 1, 2025, 00:00

  • HTA317 The Growing Role of Real-World Evidence (RWE) to Support Efficacy in EMA Oncology Approvals: Light at the End of the Tunnel

    Dec 1, 2025, 00:00

  • PCR101 Gaps in Evidence on Burden and HRQoL in Small-Cell Lung Cancer: Findings From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA50 Automated Excel-to-R Conversion of Health Economic Models Using the REEEVR Tool: Results of Alpha Test

    Dec 1, 2025, 00:00

  • PCR100 From Pain to Patient Preferences Patient Engagement in Early HTA for Repurposing Losartan in Osteogenesis Imperfecta

    Dec 1, 2025, 00:00

  • CO176 Pain-Related Disparities in Healthcare Expenditures Among Individuals With Cancer Evidence From the United States Medical Expenditure Panel Survey

    Dec 1, 2025, 00:00

  • HPR47 Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and Fran Lessons for Poland

    Dec 1, 2025, 00:00

  • CO73 DII Mentoring Project— Patient Associations as a Catalyst for Quality-Of-Life Improvement and Positive Economic Impact in Inflammatory Bowel Disease

    Dec 1, 2025, 00:00

  • SA4 A Systematic Literature Review of Prognostic Factors in Advanced Merkel Cell Carcinoma

    Dec 1, 2025, 00:00

  • EE655 Saving Money Improving Outcomes: A Two-Year Cost-Utility Analysis of Emergency Department Care Models for Managing Persons Presenting With a Musculoskeletal Disorder

    Dec 1, 2025, 00:00

  • HTA222 Life-Years Lost Due to Regulatory and Reimbursement Delays: A Study of Oncology Drugs Across England, Scotland, and France, 2022-2024

    Dec 1, 2025, 00:00

  • EE463 Feasibility of Building a Generic Partitioned Survival Model for Oncology: Essential Components and Technical Implementation

    Dec 1, 2025, 00:00

  • RWD140 Real-World Effectiveness of Immune Checkpoint Inhibitors Chemotherapy (ICI+CT) vs. ICI Monotherapy (ICI) in Untreated Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE602 Optimizing Therapeutic Strategies for Multiple Sclerosis in Italy: A Budget Impact Analysis

    Dec 1, 2025, 00:00

  • CO16 Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe

    Dec 1, 2025, 00:00

  • CO122 Factors Associated With Response to Patient-Reported Outcome Measures: A Systematic Review of Systematic Reviews and Meta-analyses

    Dec 1, 2025, 00:00

  • EE476 Forecasting the Rise in Direct and Indirect Costs for Lung Cancer on the Example of Poland

    Dec 1, 2025, 00:00

  • RWD106 Influencing Factors on the Health-Related Quality of Life of Middle-Aged and Elderly People in Ethnic Minority Areas of China: An Analysis Based on the Survey in a Urban Community of Guangxi Province

    Dec 1, 2025, 00:00

  • HTA158 From Theory to Practi Guidance for Identifying and Selecting Mapping Algorithms for Health Economic Models

    Dec 1, 2025, 00:00

  • EE432 Evaluating the Acceptability of Vignette Studies in Eliciting Utility Values for Rare Diseases: Perspectives From European HTA Agencies

    Dec 1, 2025, 00:00

  • EE700 The Economic Burden of Inflammatory Arthritis: A Systematic Review

    Dec 1, 2025, 00:00

  • EE379 Economic Evaluation of Dinutuximab Beta in the Maintenance Therapy of High-Risk Neuroblastoma in Brazil

    Dec 1, 2025, 00:00

  • HPR172 Registration and Access to Orphan Medicines in Türkiye: A Comparative Study With Poland and Germany

    Dec 1, 2025, 00:00

  • P38 "Tell Me a Story": A Randomized Study Comparing Tabulated and Narrative Presentations of a Discrete Choice Experiment

    Dec 1, 2025, 00:00

  • EPH163 Modeling the Public Health Impact of Nirsevimab and Maternal Vaccination With RSVpreF Against Infant Respiratory Syncytial Virus Infection in Germany

    Dec 1, 2025, 00:00

  • PCR66 Domain Attrition in the IWQOL Series and the Challenges of Factor-Only Item Reduction

    Dec 1, 2025, 00:00

  • HSD35 Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy

    Dec 1, 2025, 00:00

  • PCR41 Changes in Physical Activity of Pediatric Patients Treated With Damoctocog Alfa Pegol During the Alfa-PROTECT Clinical Trial

    Dec 1, 2025, 00:00

  • EE338 Do Public Preferences Matter? Health-Economic Evaluation of Antineoplastic Medication Considering EQ-5D Value Sets From Several Countries

    Dec 1, 2025, 00:00

  • EE118 Burden of Illness and Healthcare Resource Utilization Among Patients Newly Diagnosed With Amyotrophic Lateral Sclerosis in the United States: A Retrospective, Observational, Cohort Design Study

    Dec 1, 2025, 00:00

  • EPH264 Trends in the Number of Hospital Beds and Patient Turnover in Obstetrics and Gynecology in Hungary Between 2003 and 2023

    Dec 1, 2025, 00:00

  • HPR48 Comparative Analysis of Reimbursement Decisions for Advanced Oncology Combination Therapies in England and Japan

    Dec 1, 2025, 00:00

  • HTA293 Role of Real-World Evidence (RWE) in Pricing and Reimbursement Decisions for Rare Disease in Health Technology Assessment (HTA) Submissions Across EU4 + UK

    Dec 1, 2025, 00:00

  • HTA265 Patient Access Delays in Multi-Indication Medicines: A Review of Health Technology Assessment Timelines

    Dec 1, 2025, 00:00

  • HPR2 A Case Study: How England Implemented Its First Population Health Agreement

    Dec 1, 2025, 00:00

  • MSR223 When Excel Starts Talking Back: Unlocking the Power of Conversational AI for Health Economic Models

    Dec 1, 2025, 00:00

  • P24 A Framework for Accelerating Clinical Development With Real-World External Control Arms (ECA) in Phase 2 Trials

    Dec 1, 2025, 00:00

  • HPR180 Science at PACE? A Multi-Stakeholder Developed Framework for Accelerated Patient Access to Cancer Care

    Dec 1, 2025, 00:00

  • EE487 Health Economic Analysis of Malnutrition in the Netherlands

    Dec 1, 2025, 00:00

  • EPH196 Public Health and Economic Impact of RSVpreF Maternal Vaccination Among Infants in Five Asian Countries

    Dec 1, 2025, 00:00

  • CO11 Antibody-Drug Conjugates in Colorectal Cancer: A Scoping Review of Current Evidence and Emerging Clinical Trends

    Dec 1, 2025, 00:00

  • EE464 Fecal Microbiota Transplantation for Irritable Bowel Syndrome With Constipation: A Decision-Analytical Analysis

    Dec 1, 2025, 00:00

  • P8 Assessing the Full Life-Cycle Value of Highly Specialized Technologies and Advanced Therapy Medicinal Products in England

    Dec 1, 2025, 00:00

  • MSR112 From Evidence to Excel: Generative AI for Automated SLR Data Extractions

    Dec 1, 2025, 00:00

  • HPR109 Global Pricing Meets Domestic Policy: Analyzing the Financial Impact of the Most-Favored Nation Approach on the United States Medicine Prices

    Dec 1, 2025, 00:00

  • EE526 Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study

    Dec 1, 2025, 00:00

  • MSR171 Prediction of Query Outcomes in the Setting of Observational Studies

    Dec 1, 2025, 00:00

  • EPH102 Expert Consensus on a Definition for Children With Medical Complexity in England: A Modified Delphi Panel

    Dec 1, 2025, 00:00

  • HTA269 Paving the Path to Success for Joint Clinical Assessments: One Asset at a Time

    Dec 1, 2025, 00:00

  • SA83 Real-World Utilization Patterns of Corticosteroids in Ulcerative Colitis: Prevalence of Excessive Use in Routine Clinical Practice

    Dec 1, 2025, 00:00

  • CO254 Treatment Response in Pediatric Patients With Status Epilepticus: A Retrospective Observational Study From Saudi Arabia

    Dec 1, 2025, 00:00

  • EPH192 Prevalence of Obesity and Comorbidities Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • EPH255 The Role of Lifestyle in the Development of Fertility Issues

    Dec 1, 2025, 00:00

  • HPR128 International Reference Pricing (IRP) Analysis for Original Medicines in Türkiye in 2024

    Dec 1, 2025, 00:00

  • HTA282 Recognizing the Full Value of Novel Antibiotics: Identifying Value Elements in the Context of Antimicrobial Resistance

    Dec 1, 2025, 00:00

  • HPR49 Comparing the Time to Reimbursement of the Orphan Drug Evrysdi in Turkiye vs. Euro-5 Markets

    Dec 1, 2025, 00:00

  • CO257 Understanding XLH’s Impact: Incorporating Patient Perspectives to Develop a Comprehensive Conceptual Disease Model (CDM) to Drive Patient Engagement and the Generation of Meaningful Patient Experience Data

    Dec 1, 2025, 00:00

  • RWD137 Prevalence Utilization Patterns and Economic Impact of eGFR and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Real-World Analysis From Greece

    Dec 1, 2025, 00:00

  • MSR81 Effect of Positive Airway Pressure Therapy on Mortality in European Obstructive Sleep Apnea Patients: Post Hoc Analysis of a Global Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR52 Content Validation of a Modified PozQoL for Assessing HIV Therapies

    Dec 1, 2025, 00:00

  • EPH276 Utility Values for Dementia in Finland and Spain

    Dec 1, 2025, 00:00

  • MSR203 Traditional vs. Generative AI: A Rapid Systematic Review Assessing Accuracy and Efficiency of AI in Title/Abstract Screening

    Dec 1, 2025, 00:00

  • Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Dec 1, 2025, 00:00

  • EE44 All-Cause Healthcare Resource Use in Recurrent Respiratory Papillomatosis: A Claims-Based Comparison With Matched Controls

    Dec 1, 2025, 00:00

  • PCR173 Patient Perspectives on Disease Experiences and Value of Real-Time Self-Reported Symptom and Treatment Monitoring in Locally Advanced and Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • HPR122 Including Decision Uncertainty About the Clinically Minimal Important Differen Shifting From Risk Aversion to Risk Awareness in Drug Reimbursement Processes

    Dec 1, 2025, 00:00

  • EE641 Reducing External Plasma Dependency: Impact for the Portuguese National Health Service

    Dec 1, 2025, 00:00

  • MSR185 ShinyMMD: An Open-Source Shiny Web Application for a Computer Simulation Model for Type 2 Diabetes and Its Complications

    Dec 1, 2025, 00:00

  • EE254 Cost-Effectiveness of High-Dose vs. Adjuvanted Trivalent Influenza Vaccines in Older Adults in Korea

    Dec 1, 2025, 00:00

  • MSR15 Advancing Target Trial Emulation With Synthetic Data: The Target Trial Optimization Framework

    Dec 1, 2025, 00:00

  • HPR39 Budget Impact of Anakinra in Turkiye: An Analysis From the Social Security Institution’s Perspective

    Dec 1, 2025, 00:00

  • EE275 Cost-Effectiveness of Smartphone-Based Screening for Obstructive Sleep Apnea: A Markov Model Analysis From the German Statutory Health Insurance Perspective

    Dec 1, 2025, 00:00

  • P10 Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities From a Targeted Literature Review and Multi-Stakeholder Workshop

    Dec 1, 2025, 00:00

  • PCR231 The Impact of Inhaler Technique on the Health Outcomes and Cost Among Adults With Asthma and Chronic Obstructive Pulmonary Disease in Saudi Arabia

    Dec 1, 2025, 00:00

  • EPH195 Psychotropic Medications to Patients With Treatment-Resistant Depression in France

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
  • »